ArticleBMC genomics2025
Assessing the performance of 28 pathogenicity prediction methods on rare single nucleotide variants in coding regions.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A mono-organTranslational pediatrics · 2026Article
- Exploring the pathogenesis of a compound heterozygous variant in ATP7B associated with Wilson disease in an Iranian family.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate pathogenicity prediction of rare variants in coding regions is crucial for prioritizing candidate variants in human diseases and advancing personalized precision medicine. Although many prediction methods have been developed, it remains unclear how they perform specifically on rare variants.
resultsIn this study, the performance of 28 pathogenicity prediction methods was assessed using the latest ClinVar dataset, with a focus on rare variants and various allele frequency (AF) ranges. Ten evaluation metrics were employed to comprehensively assess the predictive performance of each method. The methods were selected based on their training approaches, including whether the training dataset was filtered by AF and whether AF was incorporated as a feature. Most methods focused on missense and start-lost variants, covering only a subset of nonsynonymous SNVs. The average missing rate of approximately 10% was observed in these variants, indicating that prediction scores were unavailable for them. MetaRNN and ClinPred, which incorporated conservation, other prediction scores, and AFs as features, demonstrated the highest predictive power on rare variants. For most methods, specificity was lower than sensitivity. Across various AF ranges, most performance metrics tended to decline as AF decreased, with specificity showing a particularly large decline.
conclusionsThese results provide insights into the strengths and limitations of each method in predicting the pathogenicity of rare variants, which may guide future improvements in predictive models. Furthermore, while AF and existing prediction scores offer valuable information for prediction methods, the identification of novel biological features is essential to overcome current limitations and further improve predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.